ATE494910T1 - Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort - Google Patents

Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort

Info

Publication number: ATE494910T1
Authority: AT; Austria
Prior art keywords: particles; boosting; composition; immune response; virus
Prior art date: 2003-07-10

Application number

AT04763176T

Other languages

English (en)

Inventor

Martin Bachmann

Katrin Schwarz

Original Assignee

Cytos Biotechnology Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-10

Filing date

2004-07-12

Publication date

2011-01-15

2004-07-12 Application filed by Cytos Biotechnology Ag filed Critical Cytos Biotechnology Ag

2011-01-15 Application granted granted Critical

2011-01-15 Publication of ATE494910T1 publication Critical patent/ATE494910T1/de

Links

230000028993 immune response Effects 0.000 title abstract 2
239000000203 mixture Substances 0.000 title abstract 2
239000002245 particle Substances 0.000 title abstract 2
102000002689 Toll-like receptor Human genes 0.000 abstract 2
108020000411 Toll-like receptor Proteins 0.000 abstract 2
208000017667 Chronic Disease Diseases 0.000 abstract 1
206010020751 Hypersensitivity Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
108091034117 Oligonucleotide Proteins 0.000 abstract 1
230000005867 T cell response Effects 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
230000007815 allergy Effects 0.000 abstract 1
230000005875 antibody response Effects 0.000 abstract 1
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
230000001684 chronic effect Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
230000003308 immunostimulating effect Effects 0.000 abstract 1
239000003446 ligand Substances 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
230000003612 virological effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10123—Virus like particles [VLP]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Virology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Communicable Diseases (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Engineering & Computer Science (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Pulmonology (AREA)
Oncology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT04763176T 2003-07-10 2004-07-12 Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort ATE494910T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US48571703P	2003-07-10	2003-07-10
PCT/EP2004/007679 WO2005004907A1 (en)	2003-07-10	2004-07-12	Packaged virus-like particles

Publications (1)

Publication Number	Publication Date
ATE494910T1 true ATE494910T1 (de)	2011-01-15

Family

ID=34062090

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04763176T ATE494910T1 (de)	2003-07-10	2004-07-12	Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort

Country Status (11)

Country	Link
US (1)	US20060251623A1 (de)
EP (1)	EP1644034B1 (de)
JP (1)	JP2009513532A (de)
KR (1)	KR20060031607A (de)
CN (1)	CN100404070C (de)
AT (1)	ATE494910T1 (de)
AU (1)	AU2004255470B2 (de)
CA (1)	CA2527102A1 (de)
DE (1)	DE602004031017D1 (de)
RU (1)	RU2375076C2 (de)
WO (1)	WO2005004907A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030026782A1 (en) *	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20030022854A1 (en)	1998-06-25	2003-01-30	Dow Steven W.	Vaccines using nucleic acid-lipid complexes
EP1450856B1 (de)	2001-09-14	2009-11-11	Cytos Biotechnology AG	VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
NZ540098A (en)	2002-10-29	2008-09-26	Coley Pharmaceutical Group Ltd	Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
US7956043B2 (en)	2002-12-11	2011-06-07	Coley Pharmaceutical Group, Inc.	5′ CpG nucleic acids and methods of use
CN101675993A (zh)	2003-03-26	2010-03-24	赛托斯生物技术公司	Melan-a肽类似物-病毒样颗粒偶联物
ES2217967B1 (es) *	2003-03-31	2006-01-01	Consejo Sup. Investig. Cientificas	Procedimiento de produccion de particulas virales vacias (vlps) del virus inductor de la bursitis infecciosa (ibdv), composiciones necesarias para su puesta a punto y su uso en la elaboracion de vacunas frente al ibdv.
US9090673B2 (en) *	2003-12-12	2015-07-28	City Of Hope	Synthetic conjugate of CpG DNA and T-help/CTL peptide
ES2307346B1 (es) *	2004-01-21	2009-11-13	Consejo Sup. Investig. Cientificas	Capsidas vacias (vlps(-vp4)) del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
ES2307345B1 (es) *	2004-01-21	2009-11-13	Consejo Sup. Investig. Cientificas	Capsidas vacias quimericas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
EP1812051A2 (de) *	2004-10-05	2007-08-01	Cytos Biotechnology AG	Vlp-antigen-konjugate und ihre verwendung als vakzine
ES2424229T3 (es) *	2005-03-18	2013-09-30	Cytos Biotechnology Ag	Proteínas de fusión de alérgenos de gato y utilización de las mismas
CA2608515A1 (en) *	2005-06-01	2007-05-10	Dow Global Technolgies Inc.	Production of multivalent virus like particles
ES2310062B1 (es) *	2005-07-15	2009-11-13	Bionostra, S.L.	Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
AU2006325225B2 (en) *	2005-12-14	2013-07-04	Cytos Biotechnology Ag	Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
AU2013204383B2 (en) *	2006-06-12	2016-09-22	Kuros Us Llc	Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages
SI2032592T1 (sl) *	2006-06-12	2013-10-30	Cytos Biotechnology Ag	Postopki za pakiranje oligonukleotidov v virusu-podobne delce RNA bakteriofagov
JP4957886B2 (ja) *	2006-06-30	2012-06-20	東レ株式会社	免疫活性化能を有するカラム
CN101611048B (zh) *	2006-12-12	2012-11-07	赛托斯生物技术公司	含有高浓度鸟嘌呤单体的寡核苷酸
WO2009030254A1 (en)	2007-09-04	2009-03-12	Curevac Gmbh	Complexes of rna and cationic peptides for transfection and for immunostimulation
JPWO2010024284A1 (ja) *	2008-09-01	2012-01-26	国立大学法人北海道大学	魚類抗ウイルスワクチン、魚類免疫賦活剤、および魚類免疫付与方法
WO2010042755A2 (en) *	2008-10-08	2010-04-15	Chimeros Inc.	Chimeric therapeutics, compositions, and methods for using same
WO2010042751A2 (en) *	2008-10-08	2010-04-15	Chimeros Inc.	Chimeric therapeutics, compositions, and methods for using same
WO2010042749A2 (en) *	2008-10-08	2010-04-15	Chimeros Inc.	Chimeric therapeutics, compositions, and methods for using same
ES2560782T3 (es) *	2008-11-04	2016-02-22	Index Pharmaceuticals Ab	Compuestos y métodos para el tratamiento de enfermedades inflamatorias del SNC
US20120263743A1 (en) *	2009-04-30	2012-10-18	Cytos Biotechnology Ag	Influenza hemagglutinin compositions and uses thereof
DE102009034779A1 (de)	2009-07-25	2011-02-03	Emc Microcollections Gmbh	Synthetische Analoga bakterieller Lipopeptide und ihre Anwendung zur Therapie und Prophylaxe allergischer Erkrankungen
US20110053829A1 (en)	2009-09-03	2011-03-03	Curevac Gmbh	Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
DK2707480T3 (da)	2011-05-13	2017-11-13	Folia Biotech Inc	Viruslignende partikler og fremgangsmåde til fremstilling heraf
EP3275464A1 (de) *	2011-08-01	2018-01-31	Emory University	Liganden-haltige vlps und entsprechende verfahren
US9683020B2 (en) *	2011-08-01	2017-06-20	Emory University	VLPS containing ligands and methods related thereto
GB201113570D0 (en) *	2011-08-05	2011-09-21	Glaxosmithkline Biolog Sa	Vaccine
EP2794662A1 (de)	2011-12-22	2014-10-29	F.Hoffmann-La Roche Ag	System zur anzeige eines antikörpers in voller länge für eukaryotische zellen und seine verwendung
WO2013113326A1 (en)	2012-01-31	2013-08-08	Curevac Gmbh	Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
CN103421117B (zh) *	2012-05-16	2016-08-03	李岱宗	一种免疫增强型病毒样颗粒、其表达载体及其制备与应用
EP2968528B1 (de) *	2013-03-15	2022-02-23	Sementis Limited	Immunmodulation
WO2014157692A1 (ja)	2013-03-29	2014-10-02	大日本住友製薬株式会社	Ｗｔ１抗原ペプチドコンジュゲートワクチン
CA2919268C (en)	2013-07-25	2023-09-05	Exicure, Inc.	Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
BR112016003361A2 (pt)	2013-08-21	2017-11-21	Curevac Ag	vacina do vírus sincicial respiratório (rsv)
WO2015149944A2 (en)	2014-04-01	2015-10-08	Curevac Gmbh	Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
WO2015172128A1 (en) *	2014-05-09	2015-11-12	Indiana University Research And Technology Corporation	Methods and compositions for treating hepatitis b virus infections
AU2015269412B2 (en)	2014-06-04	2020-03-12	Exicure Operating Company	Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
MA40824A (fr)	2014-10-22	2017-08-29	Saiba Gmbh	Particules de cmv de type virus modifié
WO2016081911A2 (en)	2014-11-21	2016-05-26	Northwestern University	The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
AU2016207099C1 (en)	2015-01-15	2021-02-04	University Of Copenhagen	Virus-like particle with efficient epitope display
ES2993462T3 (en) *	2015-05-20	2024-12-30	Sumitomo Pharma Co Ltd	Combination of wt1 antigen peptide, immunomodulator and wt1 helper peptide
WO2017071713A1 (en)	2015-10-30	2017-05-04	University Of Copenhagen	Virus like particle with efficient epitope display
US20190046638A1 (en) *	2016-04-01	2019-02-14	Checkmate Pharmaceuticals, Inc.	Fc RECEPTOR-MEDIATED DRUG DELIVERY
WO2017186808A1 (en) *	2016-04-27	2017-11-02	Allergy Therapeutics (Uk) Limited	Treatment of peanut allergy
WO2018039629A2 (en)	2016-08-25	2018-03-01	Northwestern University	Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018101309A1 (ja)	2016-11-30	2018-06-07	大日本住友製薬株式会社	Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
WO2018201090A1 (en)	2017-04-28	2018-11-01	Exicure, Inc.	Synthesis of spherical nucleic acids using lipophilic moieties
WO2019160866A2 (en)	2018-02-13	2019-08-22	Checkmate Pharmaceuticals, Inc.	Compositions and methods for tumor immunotherapy
BR112020020479A2 (pt)	2018-04-09	2021-01-12	Checkmate Pharmaceuticals	Empacotamento de oligonucleotídeos em partículas similares a vírus
WO2020121062A1 (en) *	2018-12-12	2020-06-18	Anergis S.A.	Methods of improving efficacy of allergy vaccines
CN111166727A (zh) *	2019-11-15	2020-05-19	河南省生物工程技术研究中心	一种肿瘤免疫治疗复合物及其制备方法和用途
CU20200028A7 (es) *	2020-04-20	2021-11-04	Ct Ingenieria Genetica Biotecnologia	Nucleoproteína viral y formulaciones que la contienen
EP4304640A1 (de) *	2021-03-12	2024-01-17	Northwestern University	Antivirale impfstoffe mit kugelförmigen nukleinsäuren
GB202204803D0 (en) *	2022-04-01	2022-05-18	Univ Manchester	Virus-like particles

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4912094B1 (en) *	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
EP1690935A3 (de) *	1990-01-12	2008-07-30	Abgenix, Inc.	Bildung von xenogenen Antikörpern
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6239116B1 (en) *	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
AU713040B2 (en) *	1994-07-15	1999-11-18	University Of Iowa Research Foundation, The	Immunomodulatory oligonucleotides
US6429199B1 (en) *	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
US6406705B1 (en) *	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU760795B2 (en) *	1998-05-14	2003-05-22	Coley Pharmaceutical Gmbh	Methods for regulating hematopoiesis using CpG-oligonucleotides
WO2001022972A2 (en)	1999-09-25	2001-04-05	University Of Iowa Research Foundation	Immunostimulatory nucleic acids
US7264810B2 (en) *	2001-01-19	2007-09-04	Cytos Biotechnology Ag	Molecular antigen array
ES2309178T3 (es) *	2001-09-13	2008-12-16	Airsage, Inc.	Sistema y metodo para proporcionar informacion de trafico usando datos operativos y desarrollados por una red inalambrica.
EP1425040A2 (de) *	2001-09-14	2004-06-09	Cytos Biotechnology AG	Steigerung der durch virusähnliche partikel hervorgerufenen immunantwort durch in-vivo aktivierung von antigen-präsentierenden zellen
EP1450856B1 (de) *	2001-09-14	2009-11-11	Cytos Biotechnology AG	VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
ATE489969T1 (de) *	2002-06-20	2010-12-15	Cytos Biotechnology Ag	Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung

2004
- 2004-07-12 AU AU2004255470A patent/AU2004255470B2/en not_active Ceased
- 2004-07-12 US US10/563,944 patent/US20060251623A1/en not_active Abandoned
- 2004-07-12 KR KR1020057022783A patent/KR20060031607A/ko not_active Ceased
- 2004-07-12 CN CNB2004800159525A patent/CN100404070C/zh not_active Expired - Fee Related
- 2004-07-12 EP EP04763176A patent/EP1644034B1/de not_active Expired - Lifetime
- 2004-07-12 CA CA 2527102 patent/CA2527102A1/en not_active Abandoned
- 2004-07-12 AT AT04763176T patent/ATE494910T1/de not_active IP Right Cessation
- 2004-07-12 DE DE200460031017 patent/DE602004031017D1/de not_active Expired - Lifetime
- 2004-07-12 JP JP2006518174A patent/JP2009513532A/ja active Pending
- 2004-07-12 RU RU2006103853A patent/RU2375076C2/ru not_active IP Right Cessation
- 2004-07-12 WO PCT/EP2004/007679 patent/WO2005004907A1/en not_active Ceased

Also Published As

Publication number	Publication date
CN1802173A (zh)	2006-07-12
EP1644034B1 (de)	2011-01-12
JP2009513532A (ja)	2009-04-02
RU2006103853A (ru)	2007-08-20
AU2004255470B2 (en)	2010-08-19
CA2527102A1 (en)	2005-01-20
AU2004255470A1 (en)	2005-01-20
DE602004031017D1 (de)	2011-02-24
WO2005004907A1 (en)	2005-01-20
EP1644034A1 (de)	2006-04-12
RU2375076C2 (ru)	2009-12-10
CN100404070C (zh)	2008-07-23
KR20060031607A (ko)	2006-04-12
US20060251623A1 (en)	2006-11-09

Legal Events

Date	Code	Title	Description
2011-07-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE602004031017D1 (de)	2011-02-24	Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort
Yang et al.	2022	Recent advances in the development of toll-like receptor agonist-based vaccine adjuvants for infectious diseases
Mbow et al.	2010	New adjuvants for human vaccines
Cao et al.	2018	Augmentation of vaccine-induced humoral and cellular immunity by a physical radiofrequency adjuvant
ATE489969T1 (de)	2010-12-15	Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
He et al.	2015	Advances in aluminum hydroxide-based adjuvant research and its mechanism
Campbell	2016	Development of the CpG adjuvant 1018: a case study
DE60234375D1 (de)	2009-12-24	VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
Kedl et al.	2003	Epitope dominance, competition and T cell affinity maturation
Mount et al.	2013	Combination of adjuvants: the future of vaccine design
WO2004084939A8 (en)	2005-06-09	Hiv-peptide-carrier-conjugates
ATE331530T1 (de)	2006-07-15	Proteasom-influenzavirus-impfstoffzusammensetzu g
WO2005089164A3 (en)	2005-12-01	Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
ATE315405T1 (de)	2006-02-15	Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
WO2008039267A3 (en)	2008-12-31	Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
WO2004026265A3 (en)	2005-01-20	Compositions and methods for treatment of herpesvirus infections
CN116064548B (zh)	2023-07-28	一种新型CpG疫苗佐剂及其应用
ATE412428T1 (de)	2008-11-15	Antigen-raster enthaltend rankl zur behandlung von knochenerkrankungen
NO20012135L (no)	2001-06-25	Forsterkede vaksiner
CN110004150B (zh)	2023-03-10	一种具有免疫增强活性的CpG寡聚核苷酸序列及其应用
ATE450545T1 (de)	2009-12-15	Impfstoff mit lawsonia intracellularis- untereinheit
PL1649287T3 (pl)	2009-04-30	Ocena szczepionek zawierających adjuwanty
WO2007005627A3 (en)	2007-06-07	Tuberculosis antigen detection assays and vaccines
ATE404152T1 (de)	2008-08-15	Pathogene impstoffe und verfahren zur deren verwendung
CN104056266B (zh)	2016-06-29	新喋呤佐剂及含新喋呤佐剂的疫苗